EWJ vs XBI
iShares MSCI Japan ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.49% for EWJ.
- • EWJ pays a higher dividend yield (4.08%).
Side-by-side metrics
| Metric | EWJ | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.49% | 0.35% |
Dividend yield Trailing 12-month yield. | 4.08% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $20.98B | $8.30B |
YTD return | 13.55% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.80 | 1.09 |
P/E ratio | 18.38 | — |
Last price | $90.99 | $133.66 |
Inception | — | — |
Issuer | iShares | State Street |
EWJ top holdings
| 8306.T | Mitsubishi UFJ Financial Group Inc | 4.09% |
| 7203.T | Toyota Motor Corp | 3.72% |
| 6501.T | Hitachi Ltd | 2.92% |
| 6857.T | Advantest Corp | 2.87% |
| 8316.T | Sumitomo Mitsui Financial Group Inc | 2.61% |
| 8035.T | Tokyo Electron Ltd | 2.55% |
| 6758.T | Sony Group Corp | 2.51% |
| 9984.T | SoftBank Group Corp | 2.47% |
| 8411.T | Mizuho Financial Group Inc | 2.18% |
| 8058.T | Mitsubishi Corp | 2.00% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About EWJ
EWJ (iShares MSCI Japan ETF) is Japanese large- and mid-cap equities. Managed by iShares, the fund carries $21.0B in assets under management, an expense ratio of 0.49%, a dividend yield of 4.08%. Its largest holding is Mitsubishi UFJ Financial Group Inc (8306.T), which represents 4.1% of the portfolio. Real Estate is the fund's largest sector exposure at 2.3%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.